Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Urol Int
    October 2024
  1. JI G, Liu F, Chen Z, Peng J, et al
    Correlation of magnetic resonance imaging and computed tomography with biological factor expression and lymph node metastasis in aggressive prostate cancer.
    Urol Int. 2024 Oct 25:1-8. doi: 10.1159/000541953.
    >> Share

  2. YU J, Zhou K, Wang J, Mao L, et al
    Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration?resistant prostate cancer: a single-center, open-label study.
    Urol Int. 2024 Oct 15:1-13. doi: 10.1159/000541929.
    >> Share

  3. OPPOLZER IA, Schnabel MJ, Hammer S, Zilles H, et al
    Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.
    Urol Int. 2024 Oct 3:1-15. doi: 10.1159/000541753.
    >> Share

    September 2024
  4. BULBUL O, Nak D, Goksel S
    Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.
    Urol Int. 2024 Sep 30:1-12. doi: 10.1159/000541628.
    >> Share

    August 2024
  5. OBERNEDER M, Henzler T, Kriegmair M, Vag T, et al
    Prediction of clinically significant prostate cancer using multi parametric MRI, biparametric MRI and clinical parameters.
    Urol Int. 2024 Aug 31. doi: 10.1159/000541152.
    >> Share

    May 2024
  6. GLOGER S, Paulics L, Philippou C, Philippou S, et al
    Perioperative rates of incidental prostate cancer after aquablation and holmium laser enucleation of the prostate (HoLEP).
    Urol Int. 2024 May 27. doi: 10.1159/000539014.
    >> Share

    March 2024
  7. SIMSEK A, Celen S, Duran MB, Kucuker K, et al
    THE DIAGNOSTIC ACCURACY OF A COMBINATION OF PREOPERATIVE 68-Ga PSMA PET/CT AND MULTIPARAMETRIC MRI IN LOCALIZED PROSTATE CANCER.
    Urol Int. 2024 Mar 13. doi: 10.1159/000538061.
    >> Share

  8. HU S, Xiong X, Qiu S, Li J, et al
    Comparing efficacies of different exercises on androgen deprivation therapy adverse effects in prostate cancer patients: a network meta-analysis.
    Urol Int. 2024 Mar 2. doi: 10.1159/000538114.
    >> Share

    January 2024
  9. RIEDEL A, Michael M, Grunberg J, Mehralivand S, et al
    The role of multiparametric MRI (mpMRI) in the prediction of adverse prostate cancer pathology in radical prostatectomy specimen.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536256.
    >> Share

  10. WU S, Feldman AS, Lin SX, Kim MM, et al
    Estimated Prostate Volume by Semiautomatic Segmentation of MRI Is More Accurately Correlated with Radical Prostatectomy Specimen Weight than the Volume Calculated by Ellipsoid Formula.
    Urol Int. 2024;108:35-41.
    >> Share

  11. SIGG S, Arnold W, Grossmann NC, Baumeister P, et al
    Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic Survey.
    Urol Int. 2024;108:211-218.
    >> Share

  12. FARZAT M, Wagenlehner FM
    How Might the Number of Lymph Nodes Removed during RARP Impact the Postoperative Outcomes?
    Urol Int. 2024;108:175-182.
    >> Share

    November 2023
  13. CANKAYA S, Caylan AE, Aydin F, Ucar M, et al
    Correlation between prostate cancer positive cores and 68Ga-PSMA distribution in prostate gland.
    Urol Int. 2023 Nov 28. doi: 10.1159/000535466.
    >> Share

  14. CUI Y, Zhao J, Sun Y
    The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Urol Int. 2023 Nov 27:1-6. doi: 10.1159/000534597.
    >> Share

  15. SENEL S, Koudonas A, Uzun E, Ceviz K, et al
    The Value of Prostate-Specific Antigen Density in Combination with Lesion Diameter for the Accuracy of Prostate Cancer Prediction in Prostate Imaging-Reporting and Data System 3 Prostate Lesions.
    Urol Int. 2023 Nov 20:1-6. doi: 10.1159/000534805.
    >> Share

  16. SIKIC D, Fiebig C, Wullich B, Wolff I, et al
    Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.
    Urol Int. 2023 Nov 6:1-10. doi: 10.1159/000534486.
    >> Share

    June 2023
  17. LONG J, Liu Z, Liang S, Chen B, et al
    Cruciferous Vegetable Intake and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2023 Jun 21:1-11. doi: 10.1159/000530435.
    >> Share

  18. FERNANDEZ-ANGUITA PJ, Ventosa-Puig M, Diaz de Mera-Sanchez Migallon I, Legido-Gomez O, et al
    Value of Prostate-Specific Antigen Kinetics in Patients with Low-Risk Prostate Cancer under Active Surveillance.
    Urol Int. 2023 Jun 16:1-7. doi: 10.1159/000530963.
    >> Share

    April 2023
  19. YOO S, Lee KH, Jamrasi P, Cho MC, et al
    Effects of Exercise on Physical Function and Quality of Life in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: High-Intensity Interval Training versus Moderate-Intensity Continuous Training.
    Urol Int. 2023 Apr 25:1-8. doi: 10.1159/000527839.
    >> Share

  20. MEYER L, Bohlscheid A, Lemmer O, van de Plas J, et al
    MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 T.
    Urol Int. 2023 Apr 18:1-9. doi: 10.1159/000529873.
    >> Share

  21. BAHLBURG H, Tully K, Hoffmann V, Hanske J, et al
    Avoiding Prostate Biopsies in Patients at Low Risk for Prostate Cancer: A Prospective Evaluation of a PSA-Density-Based Safety Net.
    Urol Int. 2023 Apr 14:1-6. doi: 10.1159/000529946.
    >> Share

  22. QIAN L, Wang Y, Xiong Y, Ren H, et al
    LINC01002 Targets miR-650/FLNA Pathway to Suppress Prostate Cancer Progression.
    Urol Int. 2023 Apr 11:1-13. doi: 10.1159/000529947.
    >> Share

    March 2023
  23. WANG Y, Chen X, Liu K, Liu R, et al
    Predictive Factors for Gleason Score Upgrading in Patients with Prostate Cancer after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    Urol Int. 2023 Mar 29:1-20. doi: 10.1159/000528873.
    >> Share

    February 2023
  24. LOPCI E, Lazzeri M, Colombo P, Casale P, et al
    Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
    Urol Int. 2023 Feb 1:1-7. doi: 10.1159/000528720.
    >> Share

    January 2023
  25. FLEGAR L, Thoduka SG, Mahnken AH, Figiel J, et al
    Focal Therapy for Renal Cancer: Comparative Trends in the USA and Germany from 2006 to 2020 and Analysis of the German Health Care Landscape.
    Urol Int. 2023;107:396-405.
    >> Share

  26. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    >> Share

  27. SCARCIA M, Moretto S, Zazzara M, Alba S, et al
    Robot-Assisted Extraperitoneal Radical Prostatectomy for Giant Multilocular Prostatic Cystadenoma: A Case Report and Literature Review.
    Urol Int. 2023;107.
    >> Share

  28. STOLZENBACH LF, Fankhauser CD, Mattei A, Wurnschimmel C, et al
    Solitary Fibrous Tumor of the Prostate Treated with Frozen-Section Supported Robot-Assisted Nerve-Sparing Radical Prostatectomy.
    Urol Int. 2023;107.
    >> Share

    November 2022
  29. SOTOMAYOR PC, Aguilar JC, Mujica K, Zuniga A, et al
    Active Surveillance in Prostate Cancer: Current and Potentially Emerging Biomarkers for Patient Selection Criteria.
    Urol Int. 2022 Nov 7:1-13. doi: 10.1159/000527151.
    >> Share

    October 2022
  30. BORKOWETZ A, Linxweiler J, Fussek S, Wullich B, et al
    The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.
    Urol Int. 2022 Oct 4:1-10. doi: 10.1159/000526598.
    >> Share

    March 2022
  31. WU J, Wei Y, Li T, Lin L, et al
    DNA Methylation-Mediated Lowly Expressed AOX1 Promotes Cell Migration and Invasion of Prostate Cancer.
    Urol Int. 2022 Mar 30:1-9. doi: 10.1159/000522634.
    >> Share

  32. MAKINO K, Sato Y, Takenaka R, Yamashita H, et al
    Cumulative Incidence and Clinical Risk Factors of Radiation Cystitis after Radiotherapy for Prostate Cancer.
    Urol Int. 2022 Mar 15:1-7. doi: 10.1159/000521723.
    >> Share

  33. HIGASHIYAMA S, Yoshida A, Kawabe J
    Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONE Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
    Urol Int. 2022 Mar 4:1-7. doi: 10.1159/000522046.
    >> Share

    February 2022
  34. JIN C, Bian Z, Mo F, Zhu C, et al
    Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer.
    Urol Int. 2022 Feb 18:1-9. doi: 10.1159/000519329.
    >> Share

  35. SOKMEN BK, Sokmen D, Comez YI, Eksi M, et al
    Prediction of Prostate Cancer Aggressiveness Using a Novel Multiparametric Magnetic Resonance Imaging Parameter: Tumor Heterogeneity Index.
    Urol Int. 2022 Feb 11:1-8. doi: 10.1159/000521606.
    >> Share

  36. BORKOWETZ A, Blana A, Bohmer D, Cash H, et al
    German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy.
    Urol Int. 2022 Feb 10:1-9. doi: 10.1159/000521882.
    >> Share

  37. CAFUTA B, Distler FA, Wagner A, Pahernik S, et al
    Salvage Radiotherapy for Recurrent Prostate Cancer after High-Intensity Focused Ultrasound Therapy: Quality of Life and Functional Outcome.
    Urol Int. 2022 Feb 1:1-6. doi: 10.1159/000521660.
    >> Share

    January 2022
  38. PORCARO AB, Panunzio A, Tafuri A, Cerrato C, et al
    The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Urol Int. 2022 Jan 26:1-12. doi: 10.1159/000521260.
    >> Share

  39. HARLAND N, Russo GI, Kaufmann S, Amend B, et al
    Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy.
    Urol Int. 2022;106:90-96.
    >> Share

  40. WETTERAUER C, Federer-Gsponer JR, Leboutte FDJP, Mona R, et al
    Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies.
    Urol Int. 2022;106:83-89.
    >> Share

  41. HAEUSER L, Reese SW, Paciotti M, Noldus J, et al
    Surgical Complications Requiring Intervention in Open versus Minimally Invasive Radical Prostatectomy.
    Urol Int. 2022;106:51-55.
    >> Share

  42. PFISTER D, Nestler T, Hartmann F, Haidl F, et al
    Feasibility and Oncologic Outcome of Salvage Surgery in Isolated Seminal Vesicle Remnants after Radical Prostatectomy.
    Urol Int. 2022;106:44-50.
    >> Share

  43. DING XF, Luan Y, Xia AL, Zhu LY, et al
    Application of 16 G Biopsy Needle in Transperineal Template-Guided Prostate Biopsy.
    Urol Int. 2022;106:909-913.
    >> Share

  44. SONG JA, He BM, Li HS, Yu XW, et al
    A Prospective Study Comparing Cancer Detection Rates of Transperineal Prostate Biopsies Performed by Junior Urologists versus a Senior Consultant in a Real-World Setting.
    Urol Int. 2022;106:884-890.
    >> Share

  45. KOZARIS R, Hanske J, von Landenberg N, Berg S, et al
    Psychosocial Distress in the Early Recovery Period after Radical Prostatectomy.
    Urol Int. 2022;106:891-896.
    >> Share

  46. ZHANG Z, Liang C
    Recurrent Prostatic Stromal Tumor of Uncertain Malignant Potential Combined with Concurrent Prostatic Adenocarcinoma: An Unusual Case.
    Urol Int. 2022;106:974-978.
    >> Share

    December 2021
  47. CROCEROSSA F, Carbonara U, Parekh J, Urdaneta A, et al
    PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
    Urol Int. 2021 Dec 21:1-8. doi: 10.1159/000520684.
    >> Share

  48. BERG S, Tully KH, von Landenberg N, Bahlburg H, et al
    How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer.
    Urol Int. 2021 Dec 20:1-6. doi: 10.1159/000520598.
    >> Share

    November 2021
  49. FLEGAR L, Baunacke M, Buerk BT, Proschmann R, et al
    Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD(R)) for Localized Prostate Cancer.
    Urol Int. 2021 Nov 23:1-6. doi: 10.1159/000520084.
    >> Share

  50. VESTRIS PG, Giwerc A, Hennequin C, Goujon A, et al
    Operative and Midterm Oncological Outcome of Focal Salvage Cryotherapy for Localized Prostate Cancer.
    Urol Int. 2021 Nov 15:1-6. doi: 10.1159/000518980.
    >> Share

    October 2021
  51. CETIN B, Wabl CA, Gumusay O
    Optimal Treatment for Patients with Oligometastatic Prostate Cancer.
    Urol Int. 2021 Oct 26:1-10. doi: 10.1159/000519386.
    >> Share

  52. GUO Y, Tian Y, Deng Y, Lu C, et al
    Diagnostic Performance of [18F]-Labeled PET/CT Tracers for Lymph Node/Bone Metastasis and Biochemical Recurrence Detection in Advanced Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Oct 13:1-19. doi: 10.1159/000518478.
    >> Share

    September 2021
  53. LI Y, Cheng X, Zhu JL, Luo WW, et al
    Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Sep 8:1-9. doi: 10.1159/000518164.
    >> Share

    August 2021
  54. SONG P, Shu M, Yang L, Di X, et al
    The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
    Urol Int. 2021 Aug 26:1-9. doi: 10.1159/000518113.
    >> Share

  55. PETERS R, Stephan C, Jung K, Lein M, et al
    Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.
    Urol Int. 2021 Aug 25:1-6. doi: 10.1159/000517891.
    >> Share

    July 2021
  56. TIAN B, Chunxiang E, Xiang Y, Teng P, et al
    Long Noncoding RNA LIPE-AS1 Drives Prostate Cancer Progression by Functioning as a Competing Endogenous RNA for microRNA-654-3p and Thereby Upregulating Hepatoma-Derived Growth Factor.
    Urol Int. 2021 Jul 7:1-16. doi: 10.1159/000516676.
    >> Share

    June 2021
  57. FERRO M, Terracciano D, Musi G, de Cobelli O, et al
    Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies.
    Urol Int. 2021 Jun 24:1-8. doi: 10.1159/000516680.
    >> Share

    May 2021
  58. KOPP D, Kopp J, Bernhardt E, Manka L, et al
    68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Urol Int. 2021 May 7:1-7. doi: 10.1159/000515651.
    >> Share

  59. PORCARO AB, Siracusano S, Amigoni N, Tafuri A, et al
    The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection.
    Urol Int. 2021 May 7:1-9. doi: 10.1159/000514391.
    >> Share

  60. CELIK S, Kizilay F, Yorukoglu K, Aslan G, et al
    Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey.
    Urol Int. 2021 May 5:1-9. doi: 10.1159/000513658.
    >> Share

    January 2021
  61. MAURER V, Stahlberg J, Schiffmann I, Marks P, et al
    Continence and Complication Rates of Artificial Urinary Sphincter Devices (AMS 800) for Parkinson and Stroke Patients with Incontinence after Prostate Surgery: Retrospective Analysis of a Prospective Database.
    Urol Int. 2021;105.
    >> Share

  62. SHEN Q, Zhou Z, Liu Z, Hu S, et al
    Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases.
    Urol Int. 2021;105.
    >> Share

  63. GOSSLER C, May M, Breyer J, Stojanoski G, et al
    High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection.
    Urol Int. 2021;105.
    >> Share

  64. XU B, Ma BL, Peng YJ, Zhang Q, et al
    Learning Curve of an Innovative "3-Port" Laparoscopic Radical Prostatectomy: A Single-Center Analysis from 2016 to 2019.
    Urol Int. 2021;105.
    >> Share

  65. SCHMITZ-DRAGER BJ, Muhlich S, Lange C, Benderska-Soder N, et al
    Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
    Urol Int. 2021;105.
    >> Share

  66. APFELBECK M, Schlenker B, Chaloupka M, Stief CG, et al
    Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature.
    Urol Int. 2021;105.
    >> Share

  67. NAKANISHI Y, Ito M, Kataoka M, Ikuta S, et al
    Who Can Avoid Biopsy of Magnetic Resonance Imaging-Negative Lobes without Compromising Significant Cancer Detection among Men with Unilateral Magnetic Resonance Imaging-Positive Lobes?
    Urol Int. 2021;105.
    >> Share

  68. PRATSINIS M, Babst C, Langenauer J, Schmid HP, et al
    Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions.
    Urol Int. 2021;105.
    >> Share

  69. MASSANOVA M, Robertson S, Barone B, Dutto L, et al
    The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study.
    Urol Int. 2021;105.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016